Results 251 to 260 of about 158,419 (290)

Urticarial Plaques With Vesicles in a Young Hispanic Woman

open access: yes
JEADV Clinical Practice, EarlyView.
Valeria Olvera‐Rodríguez   +6 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Methotrexate

Home Healthcare Now, 2015
The purpose of this article is to educate healthcare professionals about the many uses of the drug Methotrexate. Information regarding dosing, action, contraindications, adverse effects, drug interactions, as well as tips for patient education are included.
Pile, Kevin (R17082), Graham, Garry G.
  +8 more sources

Pharmacokinetics of methotrexate

Clinical Pharmacology & Therapeutics, 1973
Methotrexate (Mtx) is a competitive inhibitor of the enzymatic activity of dihydrofolate reductase, decreasing the reduction of folic acid to tetrahydrofolate and thereby the activity of thymi dilate kinase. The net effect is a decrease in biosynthesis of deoxyribonucleic acid (DNA) primarily, but also of ribonucleic acid (RNA) and protein. Whereas the
D H, Huffman   +3 more
openaire   +4 more sources

METHOTREXATE IN PSORIASIS

The Lancet, 1968
SUMMARY. Seventeen patients with widespread psoriasis were treated with parenteral methotrexate over a period of 2–88 weeks. The injections were given every 1–4 weeks, in a dose of 12·5–37·5 mg. The best results were obtained with a dose of 25 mg. of methotrexate once weekly.
Harvey Baker, TerenceJ Ryan
  +12 more sources

Leflunomide and methotrexate

Current Opinion in Rheumatology, 2001
Methotrexate and leflunomide are both effective drugs in the treatment of patients with rheumatoid arthritis. Methotrexate has been available for many years, whereas leflunomide is a relatively new drug. Several large trials describing its efficacy and safety in comparison with both sulfasalazine and methotrexate and with placebo have been published ...
Laan, R.F.J.M.   +2 more
openaire   +4 more sources

Pharmacokinetics of Methotrexate and 7-Hydroxy-Methotrexate After Methotrexate Infusions

Cancer Drug Delivery, 1987
Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and
S Just   +4 more
openaire   +3 more sources

Methotrexate for Psoriasis

Archives of Dermatology, 1967
Methotrexate is used for psoriasis by the majority of teaching services of dermatology in the United States. Three modes of administration were compared: small daily doses by mouth in interrupted schedules, single large weekly oral doses, and parenteral doses.
Harry L. Arnold   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy